

# Expanded Cancer Source Check: Ivermectin + Mebendazole, Hulscher paper, and prior cancer reports

PBC Health working PDF · built 2026-08-23 · Source URL: Facebook Reel 1374908634170174 / InfoWars “Ivermectin & Mebendazole”

**Medical boundary:** This document is not medical advice, not a protocol, and not a recommendation to start, stop or replace cancer treatment. Do not self-medicate with ivermectin, mebendazole, animal formulations, or “horse paste.” Bring the studies to a licensed oncologist/pharmacist if you want a professional review.

**Bottom line:** The Reel points to a real 2026 Anticancer Research observational paper reporting an 84.4% self-reported “clinical benefit ratio” among follow-up respondents using ivermectin + mebendazole. But PubMed also flags an official Expression of Concern about verifiability, statistical reliability, ethical oversight, and data integrity. The paper is hypothesis-generating, not proof of cure.

| Item                  | What it says                                                                                                                          | Why it matters                                                           |
|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------|
| Reel claim            | 84% of cancer patients taking ivermectin + mebendazole said their cancer disappeared, shrunk or stopped spreading after six months... | Has caused a paper’s headline to go viral, spreading after press release |
| Main paper            | 197 prescribed via telemedicine; 122 completed 6-month follow-up; 84.4% CBR, 32.8% NE, 15.6% regression, 9.1% stable, 0.5% worse      | Self-reported CBR, 32.8% NE, 15.6% regression, 9.1% stable, 0.5% worse   |
| Expression of Concern | Journal says serious concerns were raised about verifiability/statistical reliability, ethical oversight, and data integrity          | This must be kept in mind when the 84% claim is quoted                   |
| Other evidence        | Preclinical reviews show mechanisms/cell/animal findings; review of ivermectin/albendazole evidence unresolved.                       | Research inconclusive/alleged QCT evidence                               |

**New Reel transcript excerpt:** “We found that 84% of cancer patients taking ivermectin with mebendazole declared their cancer had completely disappeared, shrunk or stopped spreading after six months... Our study is now peer reviewed and published...” The transcript also includes unsupported claims about Mel Gibson/Joe Rogan anecdotes and alleged CIA-suppressed Russian studies.

**Main paper details:** Hulscher N. et al., “Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort,” Anticancer Research, 2026;46(6):3243-3255. DOI: 10.21873/anticancer.18194. PMID: 42203321.

**Expression of Concern:** Anticancer Research, PMID 42300708, says the paper was published as hypothesis-generating, that serious scientific concerns were raised by the international medical community, and that a study reporting an 84.4% CBR must rest on a verifiably real clinical foundation and ethical oversight. The journal says it does not endorse or condone unvalidated off-label use for unapproved oncological indications.

**Included prior reports/source captures:** 2025 Springer review “Ivermectin in Cancer Treatment: Should Healthcare Providers Caution or Explore Its Therapeutic Potential?”; 2025 Gynecologic Oncology Reports “Ivermectin and gynecologic cancer: What’s the data?”; 2025 “Hope versus hype”; 2020 PMC review “Ivermectin, a potential anticancer drug derived from an antiparasitic drug”; ClinicalTrials.gov NCT05318469; MedlinePlus ivermectin safety page; FDA/DailyMed ivermectin labels/warnings; prior PBC NK-cell cancer PDF.

# Reports included / source reading list

| Report/source                   | PBC use                                                                                                                |
|---------------------------------|------------------------------------------------------------------------------------------------------------------------|
| Hulscher et al. 2026            | Observational cohort; ivermectin + mebendazole; self-reported cancer status; PMID 42203321; Expression of Concern 2026 |
| Expression of Concern 2026      | PMID 42300708; concerns about data verifiability, statistics, ethical oversight and data integrity.                    |
| Patel/Chawla/Parmar 2025        | Springer Current Oncology Reports review: promising preclinical effects but no large RCT confirmation; misinformation  |
| Mujumdar et al. 2025            | Gynecologic cancer review says data are lacking and strongly cautions use in gynecologic cancers.                      |
| Straughn 2025                   | "Hope versus hype" commentary citing evidence gaps and misinformation issues.                                          |
| Juarez et al. 2020 / PMC review | Mechanistic/preclinical review; useful for research background, not a clinical protocol.                               |
| NCT05318469                     | ClinicalTrials.gov phase I/II context for ivermectin with immunotherapy in metastatic triple-negative breast cancer    |
| MedlinePlus/FDA/DailyMed        | Human ivermectin uses, side effects, overdose concerns and warnings against animal formulations.                       |
| Prior NK-cell PDF               | Separate immune-cell therapy source check; included as background, not evidence for ivermectin/mebendazole             |

**Questions to take to an oncologist:** Is there randomized evidence for this cancer type? Are the outcome measures radiology/pathology-confirmed? What are the drug interactions with chemotherapy, immunotherapy, radiation or surgery? Is dosing human-grade and prescribed, or animal-grade/social-media dosing? Would delaying standard care change survival odds?